What is the therapeutic efficacy of ethosuximide, a Cav3.2 blocker which has demonstrated analgesic activity in animal models of irritable bowel syndrome (IBS), in patients with IBS-related abdominal pain? The gene discussed is CACNA1H; the disease is irritable bowel syndrome.